Bank of America Securities Remains Bullish on Amicus Therapeutics (FOLD) With a $13 PT

Amicus Therapeutics, Inc. (NASDAQ:FOLD) is one of the best strong buy stocks to buy under $10. In a report released on July 15, Tazeen Ahmad from Bank of America Securities reiterated a Buy rating on Amicus Therapeutics, Inc. (NASDAQ:FOLD) with a price target of $13.00.

Is Amicus Therapeutics, Inc. (FOLD) the Best Low Cost Stock to Buy According to Billionaires?

Doctors in a lab coat attending to a patient receiving enzyme replacement therapies.

Amicus Therapeutics, Inc. (NASDAQ:FOLD) reported $125.2 million in total revenues for fiscal Q1 2025, representing a 15% operational growth measured at constant exchange rates (CER) and a currency headwind of $1.4 million or 1%.

The company has cash, cash equivalents, and marketable securities totaling $250.6 million as of March 31, 2025, reflecting minute growth as compared to $249.9 million at December 31, 2024.

Amicus Therapeutics, Inc. (NASDAQ:FOLD) is a biotech company that discovers, develops, and delivers medicines to treat metabolic diseases. Its product portfolio includes the first and only approved oral precision medicine to treat Fabry disease, a clinical-stage treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio.

While we acknowledge the potential of FOLD to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than FOLD and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.